Machine brains and their discontents.

“As biotech businesses become more specialized, I find that it can be useful to stratify biotech platforms into two buckets: target companies and modality companies. So far, AI advances have been more valuable for modality companies than for target companies. Let’s break down why that is the case.” ~ learn more